China – Submission for Cosmetic Ingredients Safety is Now Operating
NMPA has officially launched the platform for the submission of cosmetic ingredients safety information. On this platform, Chinese manufacturers or authorized companies log in and submit information on ingredient safety.
Marta Pinto

Marta Pinto

Regulatory Affairs Associate

CHINESE COSMETICS REGULATION

The implementation of a new Cosmetics Supervision and Administration Regulation (CSAR) has come into force on 1st of January (2021). A pre-market approval system on new cosmetic and new ingredients was implemented in the country and seven important regulations have come into effect: Administrative Measures on Cosmetics Registration and Notification; Provisions for Management of Cosmetic Registration and Notification Dossiers; Provisions for Management of New Cosmetic Ingredient Registration and Notification Dossiers; Cosmetic Classification Rules and Catalogs; Standards for Cosmetic Efficacy Claim Evaluation; Technical Guidelines for Cosmetic Safety Assessment 2021; Inventory of Existing Cosmetic Ingredients in China 2021. (see previous post)

Last year, the National Medical Products Administration (NMPA) released the final versions of the two regulations: Provisions for Management of Cosmetic Registration and Notifications Dossiers (previously called as Instructions for Cosmetic Registration and Notification Dossiers) and Provisions for Management of New Cosmetic Ingredient Registration and Notifications Dossiers. The key goal of such regulations is to standardize and guide the registration and filing of new cosmetic materials and products. The documentation requirements for application, modification, renewal and cancellation of a cosmetic registration and notification are specified on these regulations. (see previous post)

Cosmetics will be classified according to a coding system set out by the Cosmetic Classification Rules and Catalogs. Detailed requirements for qualification for safety assessors, safety assessments and the content in the report are clarified in the Technical Guidelines for Cosmetic Safety Assessment 2021. (see previous post)

SUBMISSION PLATFORM FOR COSMETIC INGREDIENTS SAFETY INFORMATION

NMPA has officially launched the platform for the submission of cosmetic ingredients safety information. On this platform, manufacturers or authorized companies log in and submit information on ingredient safety.

In order to help companies to use the platform correctly and standardize the submissions a Technical Guidance for Submission of Cosmetic Ingredients Safety Information (translation to English is pending) was published.

Spot-checks of the information submitted in the platform will be done by the NMPA. General cosmetics containing skin-brightening ingredients (e.g., phenethyl resorcinol, which is banned) are at this moment the primary focus.

Recently, the NMPA issued a science article which indicated that a draft list of permitted cosmetic whitening agents is being prepared. This will have influence on the definition of whitening cosmetics in the country.

The Chinese legal framework on cosmetics can be tricky and hard to understand, but Critical Catalyst has a team of experts that can help you. Please feel free to contact us using our email info@criticalcatalyst.com.

References:

  1. China to Release a List of Permitted Cosmetic Whitening Ingredients. Chemlinked. Dec 22, 2021. Available at: https://cosmetic.chemlinked.com/news/cosmetic-news/china-to-release-a-list-of-permitted-cosmetic-whitening-ingredients
  2. Breaking! China Launches the Long-Awaited Submission Platform for Cosmetic Ingredients Safety Information. Chemlinked. Dec 31, 2021. Available at: https://cosmetic.chemlinked.com/news/cosmetic-news/breaking-china-launches-the-long-awaited-submission-platform-for-cosmetic-ingredients-safety-information?utm_source=edm

further
reading

medical devices

Safety Reporting in Clinical Investigations: a Gap Analysis of Guidance Documents 

Safety reporting in clinical investigations of medical devices shall be performed in line with Article 80(2) of the EU MDR. On May 2020, it was published the MDCG 2020-10/1, outlining the procedures for safety reporting in clinical investigations of medical devices under the EU MDR. However, on October 2022 the Medical Device Coordination Group (MDCG) published an updated version of the MDCG 2020-10/1, the MDCG 2020-10/1 Rev 1. This article highlights the updates included in the new revision, analysing the gaps between both documents.

Read More »
medical devices

Roles and Responsibilities of an Authorised Representative under EU MDR and IVDR 

If a medical device manufacturer is not established in a Member State, the devices can only be placed on the Union market if the manufacturer designates an authorised representative. The authorised representative plays a pivotal role in ensuring the compliance of the devices with EU regulation, serving as point of contact. The obligations and responsibilities of authorised representative are outlined on Article 11 of both MDR and IVDR, but clarification of relevant requirements is described in MDCG 2022-16 of October 2022.

Read More »
medical devices

Understanding the ISO Standards Lifecycle

ISO Standards cover a huge range of activities, representing the distilled wisdom of people with expertise in their subject matter and providing the regulators with a sound basis to develop better legislation. ISO Standards are diverse, addressing from the shoe size we wear to the quality of air we breathe. The medical device sector is no exception. ISO has many International Standards and guidance documents aimed at helping the sector ensure safe and effective medical devices while meeting the multitude of national, regional and international regulatory requirements. But how exactly is a Standard developed, reviewed and withdraw?

Read More »
medical devices

Amendments to the Transitional Provisions of the European Union MDR and IVDR

The proposed amendments aim to maintain patients’ access to a wide range of medical devices while ensuring the transition to the new framework. The ammendments proposal aims to extend the current transition period (Article 120 of the MDR), and it also deletes the ‘sell-off’ deadlines of both MDR and IVDR. The extension is staggered depending on the risk class of the device – until December 2027 for high-risk devices and December 2028 for medium and lower-risk devices.

Read More »
medical devices

EU MDR – Proposal for Extension of Transition Period

The transition to MDR has been slower than anticipated by the European Commission. Insufficient capacity of notified bodies and the low level of preparedness of manufacturers led to a proposal for extension of current MDR transition period with deadlines depending on the risk class of the devices.

Read More »
medical devices

MDCG 2022-18 – EU MDR Article 97

EU MDR Article 97 may be a temporary solution to avoid disruption of supply of Medical Devices on the EU Market. The MDCG 2022-18 presents a uniform approach for application of MDR Article 97 on non-compliant legacy devices under the conditions set by the competent authorities, while limiting the impact on the supply of safe and effective devices.

Read More »
parfum_fragrance_allergen_1
cosmetic products

EU to set Labelling Requirements for 56 additional Fragrance Allergens in Cosmetic Products

World Trade Organization (WTO) has been notified by the European Commission of a draft amendment to Regulation (EC) No 1223/2009 as regards labelling of fragrance allergens in Cosmetic Products. The proposed date of adoption of the new regulation is expected to be in the first half of 2023 and the propose date of entry in force 20 days from the publication in the Official Journal of the European Union.

Read More »
cosmetic products

New Amendments to the European Cosmetics Regulation – CMR Substances

The European Commission published the Commission Regulation (EU) 2022/1531, which amends Regulation (EC) No 1223/2009 in regards to the use in cosmetic products of certain substances classified as CMR. This amendment introduces new entries to Annex II and Annex III and revises an entry to Annex V to Regulation (EC) No 1223/2009.

Read More »